Dr. Lal PathLabs Limited has announced the incorporation of its wholly-owned subsidiary, DR LAL PATHLABS FZCO, in Dubai, United Arab Emirates. This strategic move, effective June 12, 2026, signifies the company’s expansion into international markets. The subsidiary aims to strategically invest in diagnostics and allied activities, including exploring potential acquisitions and joint ventures within the region.
Subsidiary Incorporation in Dubai
Dr. Lal PathLabs Limited is pleased to announce the successful incorporation of its wholly-owned subsidiary in Dubai, United Arab Emirates. The new entity has been named DR LAL PATHLABS FZCO and received its Certificate of Incorporation and Licence on June 12, 2026, from the Dubai Multi Commodities Centre (DMCC).
Strategic Objectives and Investment Focus
The newly incorporated subsidiary, DR LAL PATHLABS FZCO, is established with the strategic objective to invest in the diagnostics and allied healthcare sectors. This initiative includes exploring potential opportunities for acquisitions, forming strategic tie-ups, and entering into joint ventures within the region. The company’s investment in this subsidiary amounts to AED 1,91,35,000, divided into 19,135 shares of AED 1,000 each, representing 100% shareholding by Dr. Lal PathLabs Limited.
Background of the New Entity
DR LAL PATHLABS FZCO is incorporated in Dubai, United Arab Emirates, as of June 12, 2026. The subsidiary’s business focus aligns with the parent company’s expertise in diagnostic services, with plans to expand its reach and offerings through strategic growth initiatives. As a newly incorporated company, its turnover and size are not applicable at this stage.
Source: BSE
